Table 4 Regular use of analgesics in the absence or presence of interacting drugs
Unadjusted | Age- and sex-adjusted | |||||
|---|---|---|---|---|---|---|
Interacting druga | Absent | Present | Absent | Present | p value | Potential clinical consequence |
% (n) | % (n) | % | % | |||
Non-steroidal anti-inflammatory drugs | ||||||
Warfarin (2.5) | 12.9 (1637) | 2.8 (9) | 12.1 | 3.9 | <.001 | Increased bleeding risk |
ASA, low dose (11.7) | 13.6 (1558) | 5.8 (88) | 12.5 | 7.4 | <.001 | Increased bleeding risk |
SSRI (1.5) | 12.5 (1602) | 22.0 (44) | 11.8 | 19.5 | .001 | Increased bleeding risk |
Glucocorticoids (1.3) | 12.7 (1625) | 12.6 (21) | 11.9 | 13.0 | .672 | Increased bleeding risk |
ACE inhibitors (3.8) | 12.9 (1614) | 6.5 (32) | 12.0 | 7.8 | .007 | Diminished effect, renal impairment, hyperkalemia |
AT II antagonists (9.2) | 12.8 (1508) | 11.5 (138) | 11.8 | 12.8 | .326 | Diminished effect, renal impairment, hyperkalemia |
Other antihypertensives (18.8)b | 13.3 (1397) | 10.2 (249) | 11.8 | 12.1 | .693 | Diminished effect |
Opioids | ||||||
CNS depressants (4.9)c | 2.9 (359) | 18.1 (116) | 2.9 | 17.5 | <.001 | CNS depression, respiratory depression, falls |
Paracetamol | ||||||
Warfarin (2.5) | 13.6 (1719) | 7.1 (23) | 12.5 | 9.5 | .154 | Increased bleeding risk |